CLDN6 and neoplasm: For PFI, the higher expression of CLDN6 had a worse PFI in subgroup of weight > 80 (Figure 9A), subgroup of BMI > 30 (Figure 9B), subgroup of postmenopause (Figure 9C), subgroup of primary therapy outcome (CR) (Figure 9D), subgroup of residual tumor (R0) (Figure 9E), and subgroup of clinical stage III (Figure 9F).